ABBVIE INC

AbbVie’s $10.9B Apogee acquisition boosts oncology, protects dividends, and opens GLP‑1 growth, but careful debt and integration management remain key.

AbbVie’s pivot to regenerative science—doubling R&D, launching AI‑driven skincare and flagship retail—boosts market share, mitigates patent cliffs, and opens M&A prospects.

Discover how AbbVie’s defensive profile withstands healthcare headwinds while investors seek growth in tech and energy—an insightful look at earnings stability.

AbbVie secures EU approval for a high‑response bispecific antibody in relapsed follicular lymphoma, boosting its oncology portfolio and investor appeal.

AbbVie’s expanding small‑molecule autoimmune pipeline—especially RINVOQ for SLE—blends steroid‑sparing data, pricing strategy, and M&A insight to target a $15 billion market while navigating patent cliffs.

AbbVie’s strategic playbook for Tardive Dyskinesia: market‑share, pipeline, pricing, and M&A plans to beat patent cliffs and sustain $3.2 B market dominance.

AbbVie’s Q2 2026 filing reveals how rising R&D and milestone costs will shape earnings, while reaffirming EPS guidance amid partnership uncertainty and regulatory risk.

AbbVie’s EU approval of bispecific antibody epcoritamab, paired with lenalidomide and rituximab, boosts lymphoma treatment prospects, driving strong market access and solid commercial returns.

AbbVie’s July 2026 insider filings show routine option exercises, boosting investor confidence as the pharma sector gains 4‑5% and the stock climbs 1.2%.

AbbVie’s July 2026 moves—insider equity purchases, the Apogee Therapeutics acquisition and a new Phase 2 oncology trial—show a strategic pivot to diversify its biologics pipeline, beat the Humira patent cliff and boost shareholder confidence.